BioSpace News Archive

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced it is expanding the age eligibility criterion to include children ages 5 to 17 years, previously restricted to ages 13 to 17 years.

Repairon together with the University Medical Center Göttingen (UMG) and the University Medical Center Schleswig-Holstein (UKSH), Campus Lübeck, as well as the German Center for Cardiovascular Research (DZHK) today announced the completion of enrolment and follow-up of patients in the dose-finding cohort of the BioVAT-HF-DZHK20 Phase 1/2 trial.

DarioHealth Corp., a leader in the global digital therapeutics market, announced that digital health veteran, Eitan Shay, is joining the Company in the newly created position of Chief Product Officer.

After twenty years as one of the first personalized oncology companies, Indivumed announced its evolution into Indivumed Therapeutics after the acquisition of Indivumed Services GmbH and its CRO service offerings by Crown Bioscience.

Flamingo Therapeutics announced the appointment of Andrew E. Denker, MD, PhD., as Chief Medical Officer.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced that members of the Zimmer Bioment management team will be presenting at the Needham Virtual Healthcare Conference on Tuesday, April 18, 2023, at 10:15 a.m. Eastern Time.